Filing Details
- Accession Number:
- 0001209191-20-007038
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-05 20:02:57
- Reporting Period:
- 2020-02-03
- Accepted Time:
- 2020-02-05 20:02:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1340652 | Chemocentryx Inc. | CCXI | Pharmaceutical Preparations (2834) | 943254365 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1422995 | J. Markus Cappel | C/O Chemocentryx, Inc. 850 Maude Avenue Mountain View CA 94043 | Chief Bus. Officer & Treasurer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-02-03 | 48,471 | $8.19 | 124,718 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-03 | 48,471 | $44.47 | 76,247 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-02-05 | 13,150 | $8.19 | 89,397 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-05 | 13,150 | $47.03 | 76,427 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2020-02-03 | 48,471 | $0.00 | 48,471 | $8.19 |
| Common Stock | Stock Option (right to buy) | Disposition | 2020-02-05 | 13,150 | $0.00 | 13,150 | $8.19 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 92,901 | 2025-02-23 | No | 4 | M | Direct | |
| 79,751 | 2025-02-23 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $43.99 to $44.84 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $46.99 to $47.16 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- As of February 3, 2020, and prior to this transaction, the exercised options were fully vested.
- Not applicable.
Billionaire Hedge Funds
